ReviewAnnals of medicine2020
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.
Review in Annals of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04613167. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic, Biochemical and Functional Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment Options
Influence of Pelacarsen on Arterial Wall Properties and Risk Factors in Patients After Myocardial Infarction With High Lp(a) Values
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- The association between lipoprotein(a) and atrial fibrillation: A systemic review and meta-analysis.Clinical cardiology · 2023Pooled it
- Lipoprotein (a) Levels and Abdominal Aortic Aneurysm. A Systematic Review and Meta-analysis.Current pharmaceutical design · 2022Pooled it
- [Efficacy Analysis of High-flow Nasal Oxygen Therapy in Patients Accepting Single-port Video-assisted Thoracoscopic Lobectomy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Trial
- Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.Atherosclerosis plus · 2026Article
- Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies.Journal of clinical medicine · 2026Review
- Beyond the Usual Suspects: A Narrative Review of High-Yield Non-Traditional Risk Factors for Atherosclerosis.Journal of clinical medicine · 2026Review
- Unraveling Emerging Data on Lipoprotein(a)-Driven Cardiovascular Disease via Multiomics: A Review.Global heart · 2026Review
- The biology of lipoprotein(a): From genetics to molecular mechanisms.European journal of clinical investigation · 2026Review
- Influence of LDL cholesterol and Lp(a) on monocytes and macrophages in atherosclerosis.Biochemia medica · 2025Review
- The Impact of Ketogenic Capacity on Lipid Profile in Individuals with Prediabetes or Newly Diagnosed Type 2 Diabetes.International journal of molecular sciences · 2025Article
- Association of high lipoprotein (a) level with carotid atherosclerosis and all-cause mortality.American journal of preventive cardiology · 2025Article
- From Systemic Inflammation to Vascular Remodeling: Investigating Carotid IMT in COVID-19 Survivors.Viruses · 2025Article
- Cardiovascular Implications of Lipoprotein(a) and its Genetic Variants: A Critical Review From the Middle East.JACC. Asia · 2025Review
- Unusual Evolution of Carotid Atherosclerosis in a Patient with Transient Ischemic Attack.Life (Basel, Switzerland) · 2025Article
- Association between lipoprotein(a) and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis.Diabetology & metabolic syndrome · 2025Article
- Statins-Their Effect on Lipoprotein(a) Levels.Reviews in cardiovascular medicine · 2025Review
- Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review.Frontiers in cardiovascular medicine · 2025Review
- Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review.Vascular health and risk management · 2025Review
- LDL atherogenicity determined by size, density, oxidation, apolipoprotein(a), and electronegativity: an updated review.Frontiers in cardiovascular medicine · 2025Review
- A miRNA signature linked to high lipoprotein (a) and coronary calcification in familial hypercholesterolaemia.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein(a) (Lp(a)) was discovered more than 50 years ago, and a decade later, it was recognized as a risk factor for coronary artery disease. However, it has gained importance only in the past 10 years, with emergence of drugs that can effectively decrease its levels. Lp(a) is a low-density lipoprotein (LDL) with an added apolipoprotein(a) attached to the apolipoprotein B component
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.